Nothing Special   »   [go: up one dir, main page]

SG11202108756TA - Compound for the sequestration of undesirable antibodies in a patient - Google Patents

Compound for the sequestration of undesirable antibodies in a patient

Info

Publication number
SG11202108756TA
SG11202108756TA SG11202108756TA SG11202108756TA SG 11202108756T A SG11202108756T A SG 11202108756TA SG 11202108756T A SG11202108756T A SG 11202108756TA SG 11202108756T A SG11202108756T A SG 11202108756TA
Authority
SG
Singapore
Prior art keywords
sequestration
patient
compound
undesirable antibodies
antibodies
Prior art date
Application number
Other languages
English (en)
Inventor
Oskar Smrzka
Bettina Wanko
Original Assignee
Ablevia Biotech Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ablevia Biotech Gmbh filed Critical Ablevia Biotech Gmbh
Publication of SG11202108756TA publication Critical patent/SG11202108756TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/06—Peptides being immobilised on, or in, an organic carrier attached to the carrier via a bridging agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
SG11202108756T 2019-03-23 2020-03-23 Compound for the sequestration of undesirable antibodies in a patient SG11202108756TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19164784.1A EP3715374A1 (fr) 2019-03-23 2019-03-23 Composé de séquestration d'anticorps indésirables chez un patient
PCT/EP2020/058024 WO2020193486A1 (fr) 2019-03-23 2020-03-23 Composé pour la séquestration d'anticorps indésirables chez un patient

Publications (1)

Publication Number Publication Date
SG11202108756TA true SG11202108756TA (en) 2021-10-28

Family

ID=65991526

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202108756T SG11202108756TA (en) 2019-03-23 2020-03-23 Compound for the sequestration of undesirable antibodies in a patient

Country Status (17)

Country Link
US (1) US12011484B2 (fr)
EP (3) EP3715374A1 (fr)
JP (1) JP2022528736A (fr)
KR (1) KR20210142615A (fr)
CN (1) CN113631581A (fr)
AR (1) AR121036A1 (fr)
AU (1) AU2020249341A1 (fr)
BR (1) BR112021018171A2 (fr)
CA (1) CA3130187A1 (fr)
DK (1) DK3898702T3 (fr)
EA (1) EA202192085A1 (fr)
ES (1) ES2927642T3 (fr)
IL (1) IL286589A (fr)
MX (2) MX2021011635A (fr)
SG (1) SG11202108756TA (fr)
TW (1) TW202102520A (fr)
WO (1) WO2020193486A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11986536B2 (en) * 2019-03-23 2024-05-21 Ablevia Biotech Gmbh Compound for the sequestration of undesirable antibodies in a patient
JP2023542390A (ja) * 2020-09-23 2023-10-06 アブレヴィア バイオテック ゲーエムベーハー ウイルスベクターの有効性を増強するための化合物
TW202228784A (zh) * 2020-09-23 2022-08-01 奧地利商艾柏力維亞生技有限公司 用以於一患者中螯合非預期的抗ｐｅｇ抗體的化合物
WO2023180502A1 (fr) 2022-03-24 2023-09-28 Ablevia Biotech Gmbh Composé pour augmentation de l'efficacité des virus oncolytiques

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6022544A (en) * 1983-01-24 2000-02-08 The John Hopkins University Therapeutic suppression of specific immune responses by administration of oligomeric forms of antigen of controlled chemistry
US5372933A (en) 1988-10-03 1994-12-13 The Scripps Research Institute Polypeptides that mimic receptor-induced binding sites, and methods of using same
US5268454A (en) * 1991-02-08 1993-12-07 La Jolla Pharmaceutical Company Composition for inducing humoral anergy to an immunogen comprising a t cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic carrier
US6897287B1 (en) 1990-01-31 2005-05-24 Oklahoma Medical Research Foundation Ro/SSA peptide reagents for diagnosis of autoantibodies
US5578496A (en) 1991-12-19 1996-11-26 Board Of Regents, Baylor College Of Medicine Detection of autoantibodies associated with the disease myasthenia gravis
US5541287A (en) * 1992-06-09 1996-07-30 Neorx Corporation Pretargeting methods and compounds
US7888458B1 (en) 1993-11-30 2011-02-15 John B. Harley Diagnostics and therapy of epstein-barr virus in autoimmune disorders
US6406861B1 (en) 1998-10-07 2002-06-18 Cell Genesys, Inc. Methods of enhancing effectiveness of therapeutic viral immunogenic agent administration
US20010010818A1 (en) * 1998-12-09 2001-08-02 Engle Steven B. Methods and formulations for reducing circulating antibodies
EP1135167A2 (fr) 1998-12-09 2001-09-26 La Jolla Pharmaceutical Procedes et formulations permettant de reduire des anticorps circulants
US6498244B1 (en) * 1999-05-28 2002-12-24 Cell Genesys, Inc. Adeno-associated virus capsid immunologic determinants
ES2248357T3 (es) 2000-07-07 2006-03-16 Medmira Inc. Composicion de antigeno mosaico de vhc.
DK1328297T3 (da) 2000-10-16 2010-02-01 Cytoguide Aps Funktionen af en haptoglobin-hæmoglobin receptor og anvendelser heraf
US20060223114A1 (en) 2001-04-26 2006-10-05 Avidia Research Institute Protein scaffolds and uses thereof
EP1597271B1 (fr) 2003-01-31 2013-03-06 Max-Delbrück-Centrum Für Molekulare Medizin Peptides diriges contre des autoanticorps resultant de l'intolerance au froid, et leur utilisation
US20040258683A1 (en) 2003-03-30 2004-12-23 Linnik Matthew D. Methods of treating and monitoring systemic lupus erythematosus in individuals
WO2005023848A2 (fr) 2003-09-09 2005-03-17 Gardner, Rebecca, Katherine Epitopes adenoviraux
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
DE102004034008A1 (de) * 2004-07-14 2006-02-09 Rösner Research GmbH & Co.KG Verfahren zur Herstellung von Albumin-Corticoid-Konjugaten
KR101414438B1 (ko) 2005-05-20 2014-07-10 아블린쓰 엔.브이. 폰 빌레브란트 인자에 대한 단일 도메인 ｖｈｈ 항체
EP1832600A1 (fr) 2006-03-09 2007-09-12 Max-Delbrück-Centrum Für Molekulare Medizin Peptides contre autoanticorps associees du glaucome et leur utilisation.
CA2653600A1 (fr) * 2006-05-31 2007-12-06 The Children's Hospital Of Philadelphia Compositions tet procedes de detection et de modulation des reponses immunitaires induites par les lymphocytes t face a des vecteurs viraux utilises en therapie genique
FI20060946A0 (fi) * 2006-10-26 2006-10-26 Glykos Finland Oy Influenssaviruksen nukleiinihappoja ja peptidejä
EP2308514B1 (fr) * 2007-03-23 2013-06-05 to-BBB Holding B.V. Conjugés pour le transport de médicaments à travers la barrière hémato-encéphalique
WO2009027063A2 (fr) 2007-08-24 2009-03-05 Julius-Maximilians-Universität Würzburg Récepteurs peptidiques cyclisés double mutants inhibiteurs d'anticorps anti-récepteurs β1-adrénergiques
US20100280098A1 (en) * 2007-10-05 2010-11-04 Juliano Rudolph L Receptor targeted oligonucleotides
US8210547B2 (en) 2009-06-16 2012-07-03 Toyota Motor Engineering & Manufacturing North America, Inc. Active magneto-rheological spring assemblies and vehicle suspension systems incorporating the same
GB0917044D0 (en) 2009-09-29 2009-11-18 Cytoguide As Agents, uses and methods
EP2498803A4 (fr) 2009-11-13 2013-05-15 Puget Sound Blood Ct Variants d'épitopes des lymphocytes t du facteur viii à immunogénicité réduite
US20130079280A1 (en) 2010-04-13 2013-03-28 Medlmmune, Llc Fibronectin type iii domain-based multimeric scaffolds
EP2402016A1 (fr) 2010-06-29 2012-01-04 Charité - Universitätsmedizin Berlin Aptamères qui inhibent l'interaction entre un anticorps et du 1ère et 2ème loop extracellulaire de récepteur bêta 1-adrénergique humain
EP3763729B1 (fr) 2010-11-25 2022-07-06 Imcyse SA Peptides immunogènes destinés à la prévention et/ou au traitement de maladies infectieuses, de maladies auto-immunes, de réponses immunitaires aux allofacteurs, de maladies allergiques, de tumeurs, du rejet de greffe, et des réponses immunitaires dirigées contre des vecteurs viraux utilisés en thérapie génique ou en vaccination génique
EP2497828A1 (fr) 2011-03-07 2012-09-12 Charité - Universitätsmedizin Berlin Utilisation d'aptamères pour la thérapie et/ou le diagnostic des maladies auto-immunes
JP4857396B1 (ja) 2011-04-13 2012-01-18 日本製薬株式会社 融合蛋白質
ES2626881T3 (es) 2012-11-12 2017-07-26 Apitope International Nv Péptidos derivados del factor VIII para uso en el tratamiento de la hemofilia A
US9310374B2 (en) * 2012-11-16 2016-04-12 Redwood Bioscience, Inc. Hydrazinyl-indole compounds and methods for producing a conjugate
EP3059244B1 (fr) 2013-10-15 2020-08-26 The University of Tokyo Agoniste de la protéine c-met
HUE054034T2 (hu) 2014-03-13 2021-08-30 Univ Basel Mielin asszociált glikoprotein elleni IgM antitestekhez kapcsódó szénhidrát ligandumok
WO2015181393A1 (fr) * 2014-05-30 2015-12-03 Per-Johan Jakobsson Nouveaux peptides à base de sfti et cyclotide
EP2982756A1 (fr) 2014-08-04 2016-02-10 Berlin Cures Holding AG Aptamères utilisés contre les maladies associées aux autoanticorps
CN106170303B (zh) 2014-11-20 2019-10-25 法罗斯根有限公司 通过半胱天冬酶激活的前体药物
US11091591B2 (en) 2015-09-16 2021-08-17 Universität Basel Carbohydrate ligands that bind to antibodies against glycoepitopes of glycosphingolipids
UA121914C2 (uk) 2015-11-18 2020-08-10 Мерк Шарп І Доум Корп. Молекула, що зв'язує pd1 і lag3
JP7085709B2 (ja) 2016-06-20 2022-06-17 エフ－スター セラピューティクス リミテッド Ｐｄ－ｌ１及びｌａｇ－３に結合する結合分子
CN109996812A (zh) 2016-09-08 2019-07-09 加利福尼亚大学董事会 用于诊断和治疗重症肌无力的肽及其用途
WO2018102668A1 (fr) 2016-12-02 2018-06-07 The Texas A&M University System Protéines de fusion pour l'appauvrissant sélective d'anticorps spécifiques d'un antigène
CZ2016826A3 (cs) 2016-12-22 2018-07-04 Contipro A.S. Léčivý prostředek s nosičem na bázi hyaluronanu a/nebo jeho derivátů, způsob výroby a použití
US20190374650A1 (en) 2017-02-22 2019-12-12 The Regents Of The University Of Michigan Compositions and methods for delivery of polymer/biomacromolecule conjugates
SG11201908422YA (en) 2017-03-15 2019-10-30 Polyneuron Pharmaceuticals Ag Glycopolymers sequestering carbohydrate-binding proteins
BR112020000995A2 (pt) 2017-07-17 2020-09-08 Spark Therapeutics, Inc. métodos e usos de aférese

Also Published As

Publication number Publication date
EP3715374A1 (fr) 2020-09-30
EP3960769A1 (fr) 2022-03-02
AR121036A1 (es) 2022-04-13
ES2927642T3 (es) 2022-11-08
DK3898702T3 (da) 2022-09-26
BR112021018171A2 (pt) 2021-11-16
US12011484B2 (en) 2024-06-18
TW202102520A (zh) 2021-01-16
IL286589A (en) 2021-12-01
AU2020249341A1 (en) 2021-11-18
EP3898702A1 (fr) 2021-10-27
MX2024005883A (es) 2024-05-29
EA202192085A1 (ru) 2021-12-10
US20220062435A1 (en) 2022-03-03
EP3898702B1 (fr) 2022-06-29
CN113631581A (zh) 2021-11-09
MX2021011635A (es) 2022-01-04
JP2022528736A (ja) 2022-06-15
CA3130187A1 (fr) 2020-10-01
KR20210142615A (ko) 2021-11-25
WO2020193486A1 (fr) 2020-10-01

Similar Documents

Publication Publication Date Title
LT3872091T (lt) Antikūnai prieš sars-cov-2
IL286589A (en) A compound for isolating unwanted antibodies in a patient
IL289112A (en) Antibodies against tigit
IL291068A (en) Anti-cd73 antibodies
GB202012331D0 (en) Therapeutic antibodies
IL284584A (en) Anti-tigit antibodies
IL308741A (en) Anti-SIRP-alpha antibodies
GB2581174B (en) Antibodies against hEPCR
GB201905150D0 (en) Ant-ige antibodies
IL311043A (en) Anti-IL---11RA antibodies
GB201900732D0 (en) Antibodies
GB201917480D0 (en) Antibodies
IL289160A (en) Anti-angpt2 antibodies
IL308100A (en) Antibodies
IL289959A (en) Antibody purification methods
IL300142A (en) Anti-IL13Ralpha2 antibodies
GB202105110D0 (en) Anti-CD73 antibodies
GB202014851D0 (en) SARS-COV-2 antibodies
GB201919280D0 (en) Antibodies
IL310245A (en) Anti-HLA-G antibodies
GB202208773D0 (en) Anti-SARS2-S antibodies
IL308782A (en) Antibodies
IL307175A (en) IL-38 specific antibodies
GB202108677D0 (en) Therapeutic antibodies
GB202116709D0 (en) Antibodies